106 related articles for article (PubMed ID: 35245914)
21. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
[TBL] [Abstract][Full Text] [Related]
23. Treatment of opioid dependence with buprenorphine: current update.
Soyka M
Dialogues Clin Neurosci; 2017 Sep; 19(3):299-308. PubMed ID: 29302227
[TBL] [Abstract][Full Text] [Related]
24. Tele-buprenorphine for emergency department overdose visit follow up and treatment initiation.
Wightman RS; Jacka B; Uber J; McKenzie M; Reddy NG; Winters R; Jordison Keeler LA; Samuels EA
Am J Emerg Med; 2021 Dec; 50():409-412. PubMed ID: 34481260
[TBL] [Abstract][Full Text] [Related]
25. Perioperative Management of Buprenorphine: Solving the Conundrum.
Quaye AN; Zhang Y
Pain Med; 2019 Jul; 20(7):1395-1408. PubMed ID: 30500943
[TBL] [Abstract][Full Text] [Related]
26. The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation.
D'Onofrio G; Hawk KF; Herring AA; Perrone J; Cowan E; McCormack RP; Dziura J; Taylor RA; Coupet E; Edelman EJ; Pantalon MV; Owens PH; Martel SH; O'Connor PG; Van Veldhuisen P; DeVogel N; Huntley K; Murphy SM; Lofwall MR; Walsh SL; Fiellin DA
Contemp Clin Trials; 2021 May; 104():106359. PubMed ID: 33737199
[TBL] [Abstract][Full Text] [Related]
27. Clearance of buprenorphine during pregnancy and neonatal outcomes.
Coker JL; Ray-Griffith SL; McLeod C; Han X; Mancino M; Kearns GL; Stowe ZN
Arch Womens Ment Health; 2021 Dec; 24(6):933-939. PubMed ID: 33864131
[TBL] [Abstract][Full Text] [Related]
28. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
29. Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic.
Doorley SL; Ho CJ; Echeverria E; Preston C; Ngo H; Kamal A; Cunningham CO
Subst Abus; 2017; 38(1):26-30. PubMed ID: 27897918
[TBL] [Abstract][Full Text] [Related]
30. Exploring the Interactions between Non-Medical Methamphetamine Use and Prescribed Buprenorphine or Naltrexone in Opioid Use Disorder Treatment Retention.
Gainer DM; Nahhas RW; Vanderhoof T; Silverstein SM; Wright MD; Vanderhoof SO; Miller SC
Subst Use Misuse; 2021; 56(14):2160-2170. PubMed ID: 34538204
[TBL] [Abstract][Full Text] [Related]
31. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
33. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
34. Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.
Lowry N; Cowden F; Day E; Gilvarry E; Johnstone S; Murray R; Kelleher M; Mitcheson L; Marsden J
BMJ Open; 2022 Oct; 12(10):e067194. PubMed ID: 36270754
[TBL] [Abstract][Full Text] [Related]
35. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
36. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
[TBL] [Abstract][Full Text] [Related]
37. Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model.
Wallin CM; Bowen SE; Roberge CL; Richardson LM; Brummelte S
Drug Alcohol Depend; 2019 Dec; 205():107625. PubMed ID: 31706250
[TBL] [Abstract][Full Text] [Related]
38. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
[TBL] [Abstract][Full Text] [Related]
39. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.
Hill LG; Loera LJ; Evoy KE; Renfro ML; Torrez SB; Zagorski CM; Perez JC; Jones SM; Reveles KR
Addiction; 2021 Jun; 116(6):1505-1511. PubMed ID: 33140519
[TBL] [Abstract][Full Text] [Related]
40. Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program.
Hersh D; Little SL; Gleghorn A
J Psychoactive Drugs; 2011; 43(2):136-45. PubMed ID: 21858959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
